AdAPT Biotech

AdAPT Biotech is a clinical-stage biotechnology company focused on overcoming the limitations of systemic oncolytic virus delivery. The company utilizes its proprietary Advanced Adenoviral Platelet Technology (AdAPT) platform, which employs platelets as Trojan horses to protect viral payloads from neutralizing antibodies and deliver them directly to tumor sites. Its lead therapeutic candidate, ADAP-001, is an oncolytic adenovirus that expresses a TGF-beta trap to neutralize the immunosuppressive effects of the tumor microenvironment. Currently, the company is conducting Phase 1 clinical trials to evaluate the safety and efficacy of ADAP-001 in patients with refractory solid tumors. By combining viral oncolysis with immune modulation and targeted delivery, AdAPT Biotech aims to provide a more effective treatment option for hard-to-treat cancers.